A propensity score matching comparison between GnRH agonist and GnRH antagonist protocols in patients in POSEIDON groups 3 and 4  

作　　者：Jifan Tan Luxin Liu Jiaxin Jiang Yue Wu Shuchen Long Qiong Wang Jia Huang 

机构地区：[1]Reproductive Medicine Center,The First Affiliated Hospital,Sun Yat-sen University,Guangzhou,Guangdong 510080,China [2]Guangdong Provincial Key Laboratory of Reproductive Medicine,Guangzhou,Guangdong 510080,China

出　　处：《Chinese Medical Journal》2023年第4期482-484,共3页中华医学杂志（英文版）

基　　金：supported by grants from the Natural Science Foundation of Guangdong Province(No.2021A1515010290);National Natural Science Foundation of China(No.81871159);Guangdong Basic and Applied Basic research(No.2022A1515012599).

摘　　要：To the Editor:The conflicting definition of poor ovarian response has complicated the comparison of proposed treatments.The Patient Oriented Strategies Encompassing Individualized Oocyte Number(POSEIDON)classification[1]was formulated to guide individual ovarian response management through detailed stratification.POSEIDON groups 3 and 4 were defined as patients with low anti-Müllerian hormone(AMH;<1.2 ng/mL)and/or low antral follicle count(AFC;<5).

关 键 词：PATIENTS EID ANTAGONIST 

分 类 号：R71[医药卫生—妇产科学]